Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: Development and validation of risk scores for either medication in two large Dutch cohorts

Journal of Gastroenterology

Volumn 49, Issue 2, 2014, Pages 245-253

  De Groot, Nicolette L ^a   Hagenaars, Matthijs P ^a,b   Smeets, Hugo M ^a,c   Steyerberg, Ewout W ^d   Siersema, Peter D ^a   Van Oijen, Martijn G H ^a,e,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ACHMEA Health Insurance ^*  (Netherlands)

^c Agis Health Insurance   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gastrointestinal bleeding; Low dose aspirin; NSAIDs; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK FACTOR; UPPER GASTROINTESTINAL BLEEDING; VALIDATION STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANEMIA; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ASPIRIN; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; SEX FACTORS; YOUNG ADULT;

EID: 84896710924     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-013-0817-y     Document Type: Article

References (27)

1. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55(12):1731-8.
2. Garcia Rodriguez LA, Barreales TL. Risk of upper gastrointestinal complications among users of traditional NSAIDs and COXIBs in the general population. Gastroenterology. 2007;132(2):498-506.
3. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183-7.
4. Hernandez-Diaz S. Garcia Rodriguez LA. Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med. 2006;4:22.
5. Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin. 2007;23(1):163-73.
6. Bayer Pharmaceuticals. Facts about aspirin. 28-7-2000.
7. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology. 2002;123(4):1006-12.
8. Castellsague J, Holick CN, Hoffman CC, et al. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. Pharmacotherapy. 2009;29(12):1397-407.
9. Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. Aliment Pharmacol Ther. 2010;32(10):1240-8.
10. Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID users at risk for gastrointestinal complications: a systematic review of current guidelines and consensus agreements. Drug Saf. 2010;33(6):443-53.
11. Chan FK, Graham DY. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications - review and recommendations based on risk assessment. Aliment Pharmacol Ther. 2004;19(10):1051-61.
12. Lanza FL, Chan FK, Quigley EM. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728-38.
13. van Boxel OS, van Oijen MG, Hagenaars MP, et al. Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol. 2010;105(11):2430-6.
14. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61(2):235-40.
15. Steyerberg EW. Presentation formats. In: Clinical prediction models. New York: Springer Science+Business Media; 2009.
16. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American college of cardiology foundation task force on clinical expert consensus documents. Circulation. 2008;118(18):1894-909.
17. Garcia Rodriguez LA, Lin KJ, Hernandez-Diaz S, et al. Risk of upper gastrointestinal bleeding with low-dose acetylsalicylic acid alone and in combination with clopidogrel and other medications. Circulation. 2011;123(10):1108-15.
18. Lanas A, Rodrigo L, Marquez JL, et al. Low frequency of upper gastrointestinal complications in a cohort of high-risk patients taking low-dose aspirin or NSAIDS and omeprazole. Scand J Gastroenterol. 2003;38(7):693-700.
19. Hansen JM, Hallas J, Lauritsen JM, et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol. 1996;31(2):126-30.
20. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med. 1991;91(3):213-22.
21. de Abajo FJ. Garcia Rodriguez LA. Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations. BMC Clin Pharmacol. 2001;1:1.
22. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gastrointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther. 2002;16(11):1945-53.
23. Shiotani A, Sakakibara T, Yamanaka Y, et al. Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin. J Gastroenterol. 2009;44(2):126-31.
24. Shiotani A, Manabe N, Kamada T, et al. Risk and preventive factors of low-dose aspirin-induced gastroduodenal injuries: a comprehensive review. J Gastroenterol Hepatol. 2012;27(Suppl 3):8-12.
25. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ. 1995;310(6983):827-30.
26. Latimer N, Lord J, Grant RL, et al. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis. BMJ. 2009;339:b2538.
27. Cameron C, van Zanten SV, Skedgel C, et al. Cost-utility analysis of proton pump inhibitors and other gastro-protective agents for prevention of gastrointestinal complications in elderly patients taking nonselective nonsteroidal anti-inflammatory agents. Aliment Pharmacol Ther. 2010;31(12):1354-64.